Lay Summaries and Lay Summary Videos

• CYLTEZO ® - Arthritis, Rheumatoid

  Clinical Study Number	1297.2
  Study Indication	Arthritis, Rheumatoid
  Product	CYLTEZO ®
  Generic Name	Adalimumab-adbm
  Lab Code	BI 695501
  Clinical Phase	III
  Study Title	Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial
  Study Document	Lay summary 1297.2 english

• CYLTEZO ® - Arthritis, Rheumatoid

  Clinical Study Number	1297.3
  Study Indication	Arthritis, Rheumatoid
  Product	CYLTEZO ®
  Generic Name	Adalimumab-adbm
  Lab Code	BI 695501
  Clinical Phase	IIIb
  Study Title	Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis: an open-label extension trial for patients who have completed Trial 1297.2 and are eligible for long-term treatment with adalimumab (VOLTAIRE-RAext)
  Study Document	Lay summary 1297.3 english

• CYLTEZO ® - Psoriasis

  Clinical Study Number	1297.12
  Study Indication	Psoriasis
  Product	CYLTEZO ®
  Generic Name	Adalimumab-adbm
  Lab Code	BI 695501
  Clinical Phase	III
  Study Title	Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
  Study Document	Lay summary 1297.12 english Lay summary 1297.12 czech Lay summary 1297.12 estonian Lay summary 1297.12 german Lay summary 1297.12 polish Lay summary 1297.12 slovak